Drug Type Small molecule drug |
Synonyms CP 866087 |
Target |
Action antagonists |
Mechanism μ opioid receptor antagonists(Mu opioid receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H28N2O2 |
InChIKeySCNSHBHEDUUZDM-RMNGQBEXSA-N |
CAS Registry519052-04-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sexual Dysfunction, Physiological | Phase 2 | Australia | 01 Jul 2007 | |
Sexual Dysfunction, Physiological | Phase 2 | Denmark | 01 Jul 2007 | |
Sexual Dysfunction, Physiological | Phase 2 | Norway | 01 Jul 2007 | |
Sexual Dysfunction, Physiological | Phase 2 | South Africa | 01 Jul 2007 | |
Sexual Dysfunction, Physiological | Phase 2 | Sweden | 01 Jul 2007 | |
Sexual Dysfunctions, Psychological | Phase 2 | Australia | 01 Jul 2007 | |
Sexual Dysfunctions, Psychological | Phase 2 | Denmark | 01 Jul 2007 | |
Sexual Dysfunctions, Psychological | Phase 2 | Norway | 01 Jul 2007 | |
Sexual Dysfunctions, Psychological | Phase 2 | South Africa | 01 Jul 2007 | |
Sexual Dysfunctions, Psychological | Phase 2 | Sweden | 01 Jul 2007 |